NCT01067131 - Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Recurrent Vulvovaginal Candidiasis

Interventions

BIOLOGICAL

PEV7C1

capsule intravaginal application contains antigen coupled to virosomes

BIOLOGICAL

PEV7C9

capsule intravaginal application contains excipient only

BIOLOGICAL

PEV7B2

reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes

BIOLOGICAL

PEV7B1

reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes

Trial Locations (2)

CHUV, Vaccine and Immunotherapy Center, Lausanne

Covance Clinical Research Unit AG, Allschwil